Details for Patent: 7,893,074

« Back to Dashboard

Which drugs does patent 7,893,074 protect, and when does it expire?

Patent 7,893,074 protects ZYKADIA and is included in two NDAs.

This patent has ninety-two patent family members in thirty-five countries.

Summary for Patent: 7,893,074

Title:	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Abstract:	Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Inventor(s):	Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
Assignee:	Novartis AG
Application Number:	US10/568,367
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,893,074

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 7,893,074

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0319227.5	Aug 15, 2003
United Kingdom	0322370.8	Sep 24, 2003

PCT Information
PCT Filed	August 13, 2004	PCT Application Number:	PCT/EP2004/009099
PCT Publication Date:	February 24, 2005	PCT Publication Number:	WO2005/016894

International Family Members for US Patent 7,893,074

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045458
Argentina	107965
Argentina	114354
Austria	497495
Austria	542801
Australia	2004220338